Skip to main content
Premium Trial:

Request an Annual Quote

Ortho-Clinical Kills Alzheimer s License with SynX

NEW YORK, March 5 (GenomeWeb News) - Ortho-Clinical Diagnostics has ended an exclusive agreement to license certain Alzheimer's diagnostics technology from SynX Pharma, and has stopped trying to develop the technology, SynX said today.


As a result, Toronto-based SynX has re-acquired from Ortho the worldwide rights to the technology, the company said.


SynX won a USpatent for the technology in September 2002, and licensed it exclusively to Ortho one month later. SynX  said it plans to "pick up where Ortho has left off" and continue developing the Alzheimer's technology. The company will begin seeking non-exclusive licensing partners and consider plans to add it to its Nexus Dx point-of-care product line.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.